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Paul Kotzampaltiris3, Fedra Partheniou3 and Elisabeth Nacheva1,3*Abstract
ETV6-ABL1 is a rare gene fusion with oncogenic properties, reported so far in 28 patients presenting a variety of
haematological malignancies associated with clinical outcome, including chronic myeloid leukaemia (CML), acute
myeloid leukaemia (AML), acute lymphoblastic leukaemia (ALL) and chronic myeloproliferative neoplasm (cMPN). Here
we report on a 46-year-old female who presented with Philadelphia negative CML, positive for the ETV6-ABL1 fusion.
Whole genome screening carried out with oligonucleotide arrays showed a subtle loss at 12p13 and cryptic
imbalances within the 9q34.3 region in a highly unstable genome. FISH mapping with custom BAC probes identified
two breakpoints 5 Mb apart within the 9q34 region, together with a break at 12p13. While FISH with commercial BCR-
ABL1 probes failed to detect any ABL1 changes, the ETV6 break-apart probe conclusively identified the ETV6-ABL1 fusion
thus determining the probe’s role as the primary diagnostic FISH test for this chimeric oncogene. In addition, we
confirm the association of the ETV6-ABL1 fusion with imatinib resistance reported so far in three other patients, while
recording excellent response to the 2nd generation tyrosine kinase inhibitor (TKI) nilotinib. In summary, we highlight the
value of ETV6 FISH as a diagnostic test and the therapy resistance of ETV6-ABL1 positive disorders to imatinib.
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CML is one of the most extensively studied human ma-
lignancies and was the first example of a disease, where
the underlying molecular basis was a consistent chromo-
somal abnormality, the Philadelphia chromosome (Ph),
that is the product of a balanced reciprocal translocation
involving chromosomes 9 and 22. Over 95% of CML pa-
tients are found to carry the t(9;22)(q34;q11) and the re-
sultant BCR/ABL1 fusion gene as postulated by WHO
classification (2008) [1]. Six other genes in addition to
BCR can form a fusion product with ABL1. The
chimeric proteins contain the kinase domain of ABL1
and are composed of the N-terminal part of the partner
protein that includes a coiled-coil or a helix-loop-helix
domain. Fusion genes with a break within intron 1 or 2
of ABL1, such as BCR-ABL1, ZMIZ1-ABL1, EML1-ABL1
and ETV6-ABL1, carry transforming activity, while the
NUP214-ABL1 requires amplification to be efficient [2].* Correspondence: e.nacheva@ucl.ac.uk
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reproduction in any medium, provided the orThe ETV6-ABL1 fusion was reported for the first time
in a 22-month-old girl with ALL by Papadopoulos et al.
in 1995 [3] and to date, this fusion gene has been
reported in 28 cases of haematological malignancy [4-6].
Common characteristics of the ETV6-ABL1 transloca-
tion appears to be eosinophilia, seen in 16 out of the 21
patients for which data was available, a 2:1 male pre-
dominance and seen in patients with ages varying be-
tween 8 months and 81 years. The ETV6-ABL1 fusion is
seen in a wide range of haematological malignancies: 5
patients had AML, 10 ALL and 3 with an MPN while
the remaining 11 were described as having Ph negative
CML, of which 3 presented in a blast crisis, summarised
in Table 1 [3,4,7-24].
The structure of the ETV6-ABL1 oncoprotein is similar
to that of BCR-ABL1, as evidenced by the fact that both
fusion products lead to activation of the non-receptor
tyrosine kinase ABL1 with initiation of similar down-
stream pathways effecting cellular survival, growth rate
and independence as well as transforming capacity [25].
The existence of two different transcripts, type A and
B, is evidence for alternative splicing. Type A transcript
includes the first four exons of ETV6, fused to exon 2 ofral Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Summary of published data for patients with etv6/abl1 fusion gene
No Dg Sex Age TKI Outcome Eosinophilia Transcript
type
G banding FISH/ETV6 FISH/ABL1 Genome
features
Reference
1 ALL F 22 mo No Died A na na na na Papadopoulos et al, 1995 Cancer Research [3]
2 AML-M6 M 81 No Died B t(9;12;14)(q34;p13;q22)/
complex karyotype
na na na Golub et al., 1996 Mol & Cellular Biology [7]
3 CML
atypical
na 49 No Died Yes B na na na na Brunel et al., 1995 Leukemia [8]
4 CML M 32 No CR (>3Y) Yes B 46,XY,t(12;14)(p12;q11-13) 5’ETV6 on 9q34 ABL1 3’/5’ on
9q34
na Andreasson et al., 1997 Genes, Chrom & Ca [9]
5 CML M 59 No Died Yes A, 46,XY,del(6)(p21),?t(9;12)
(q34;p12)
5’ETV6 on 9q34 ABL1 3’/5’ on
9q34
na Van Limbergen et al., 2001 Genes, Chrom & Ca [10]
6 T/ALL M 4 No Died Yes A,B 47,XXYc,del(6)(q15q23) 5’ETV6 on 9q34 ABL1 3’/5’ on
9q34
na Van Limbergen et al., 2001 Genes, Chrom & Ca [10]
7 AML-M6/
CML/MBC
M 38 Yes Died na A,B 46,XY na 3’ABL1 on 12p karyotype
evolution
O’Brien et al., 2002 Blood [11]
8 CML M 53 No CR (>6Y) Yes A,B 46,XY na ABL1 3’/5’ on
9q34
na Lin et al., 2002 Leukemia [12]




na Keung et al., 2002 Ca Gen &Cytogen [13]
10 AML-M1 M 29 No CR (>20 M
post SCT)
Yes A 46,XY,t(8;12)(p21;p13) 5’ETV6 on 8p21 3’ABL1 on 8p21 na La Starza et al., 2002 Haematologica [14]
11 AML-M1
post RAEB
M 48 No Died Yes B 46,XY,t(9;12)(q34;p13) na 3’ABL1 on 12p karyotype
evolution
La Starza et al., 2002 Haematologica [14]
12 CML-MBC M 36 Yes Died Yes B 45,XY-7,t(9;12)(q34;q13) na 3’ABL1 on 12p karyotype
evolution
Barbouti et al., 2003 Br J Haematol [15]
13 CML-LBC M 72 Yes CR (>12 M) na B 46,XY,t(12;17)
(p11.2;p11.2)
5’ETV6 on 17p 3’ABL1 on 17p Tirado et al., 2005 Ca Gen & Cytogen [16]
14 cMPN F 65 No Died Yes A,B 46,XX ,t(5;9)(q13;q34) na 3’ABL1 on 12p karyotype
evolution
Meyer-Monard et al., 2005 Leukemia [17]
15 cMPN M 57 No CR (>15Y) Yes na 46,XY na 3’ABL1 on 12p na Mozziconacci et al., 2007 Amer J of Haematol [18]
16 ALL M 30 Died A,B 45,XY,del(1)(q42),-9,-13,
add(16)(p1?3),+mar
na 3’ABL1 on 12p p16 loss Baeumler et al., 2008 Ca Gen & Cytogen [19]




Kawamata et al., 2008 Genes,Chrom & Ca [20]
18 cMPN F 61 Yes CR (>3Y) Yes na 46,XX 5’-3’ETV6 on 12p 3’ABL1 on 12p na Nand et al., 2009 Leuk Research [21]
19 CML
atypical
M 79 Yes Died Yes na 46,XY 5’-3’ETV6 on 12p 3’ABL1 on 12p na Kelly et al., 2009 Ca Gen &Cytogen [22]
20 ALL F 33 Died No A,B 46,XY, der(1)t(1;?) na normal p16/p15 loss Zuna et al., 2010 Genes,Chrom & Ca [4]
21 ALL M 5 No CR (>24 M) Yes A,B 46,XY na 3’ABL1 on 12p p16/p15 loss Zuna et al., 2010 Genes,Chrom &Ca [4]
22 ALL M 8 mo Yes Died No A,B 46,XX,t(8;9;12)
(p12;q34;p13)

















Table 1 Summary of published data for patients with etv6/abl1 fusion gene (Continued)
23 ALL F 8 Yes CR( >10 M) na A,B 46.XX na 3’ABL1 on 12p? na Malone A et al., 2010 Br J Haematol [6]
24 CML M 36 Yes CR(>5Y) No 46,XY, t(9;12)(q34;p13) na 3’ABL1 on 12p normal UTX,
ASXL1, EZH2,
TET2 & IDH1/2
Perna et al., 2011 Haematologica [24]
25 T/ALL na na na na na na na na na na Zhou et al., 2012 Annual Haematology [5]
26 T/ALL na na na na na na na na na na Zhou et al., 2012 Annual Haematology [5]
27 AML M 52 No Died Yes B 46,XY[20] 5’-3’ETV6 on 12p 3’ABL1 on 12p normal FLT3,
cKit & NPM1
Park J et al., 2013 Acta Haematologica [23]
28 B/ALL F 25 No Died No A,B 46,XX,del(9)(p22),
der(10)t(9;10)(q22;p15)
5’-3’ETV6 on 12p 3’ABL1 on 12p na Park J et al., 2013 Acta Haematologica [23]
29 CML F 52 Yes CR > 12 M Yes A,B 46,XX,t(9;12)(q34;p13) 5’ETV6 on 9q34 ABL1 3’/5’ on
9q34
37 CNAs Current study
Abbreviations: ALL Acute lymphoblastic leukemia, AML Acute myeloid leukemia, CML Chronic myeloid leukemia, MPN Myeloproliferative disease, MBC Myeloid blast crisis, LBC Lymphoid blast crisis, F Female, M male, CR
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http://www.molecularcytogenetics.org/content/6/1/39ABL1, while type B includes exons 1 to 5 of ETV6 fused
to ABL1 exon 2. The difference between the two tran-
scripts at protein level is the presence or absence of a
direct binding site for the SH2 domain of the GRB2.
Million et al [26] showed that the GRB2 binding site in
the ETV6-ABL1 product has several functions - from ac-
tivation of the GAB2, PI3-kinase, and ERK-MAPK path-
ways to transformation of fibroblasts and B-lymphoid
cells all of which are required for efficient induction of
CML-like MPN. Furthermore, they demonstrated that
the absence of ETV6 exon 5 leads to a slightly lower
tyrosine kinase activity of the type A ETV6-ABL1 pro-
tein, although both kinases are as catalytically active as
is the BCR-ABL1 product.
Since the ETV6 and ABL1 genes have an opposite
orientation to the chromosome centromere, the forma-
tion of a fusion requires at least three chromosomal
breaks to be generated [2]. This could be the reason for
the well-documented low incidence of ETV6-ABL1 fu-
sion cases. Furthermore little is known regarding the ef-
fect of treatment with tyrosine kinase inhibitors on
ETV6-ABL1 fusion positive haematological conditions.
Here we report a female patient, who presented with
Philadelphia negative CML and t(9;12)(q34;p13) as a sole
bone marrow karyotype abnormality leading to ETV6-
ABL1 fusion formation. Located on der(9)t(9;12), this fu-
sion oncogene is shown to result from multiple events
within a 5.6 Mb region at 9q34.12-q34.3, which escapes
detection by commercial BCR-ABL1 FISH probes. Import-
antly, full cytogenetic and molecular remission was
achieved only after second generation TKI treatment thus
associating the ETV6-ABL1 fusion with TKI resistance.
Case report
In August 2011 a 46-year-old female presented with fa-
tigue, a leucocytosis and thrombocytosis. Blood film exam-
ination was suggestive for CML with a neutrophilia,
myelocyte peak, basophilia and also of note a eosinophilia
of 2.5 × 109/l. The aspirate morphology reported myeloid
hyperplasia with reduced erythropoiesis, and increased eo-
sinophilic and basophilic precursors. Histopathology
reported a myeloproliferative neoplasm suggestive for
CML chronic phase, with a markedly hypercellular bone
marrow and myeloid hyperplasia with a left shift and loss
of normal architecture. Erythroid activity was markedly re-
duced - only scattered CD71 positive cells were present.
CD34 and CD117 show less than 5% blasts. G-banding
identified a balanced t(9;12)(q34;p13) in 10/10 metaphases
and interphase FISH was positive in 92% of cells analysed.
RT-PCR revealed the presence of ETV6-ABL1 fusion
mRNA, while BCR-ABL1 was not detected. Such cases are
not adequately covered by the WHO classification of mye-
loproliferative disorders and could be categorized as a ?
CML variant.Imatinib therapy achieved a complete haematological
response (CHR) after 4 weeks and at 3 months, inter-
phase FISH on the peripheral blood was positive in 37/
200 cell (18.5%). At 5 months thrombocytosis had re-
curred with the reappearance of a mild neutrophilia, ba-
sophilia and eosinophilia at 6 months. FISH analysis was
positive in both interphase (50/200) and metaphase (6/
20) cells and residual disease was confirmed by nested
RT-PCR. She was switched to nilotinib, once again
achieving a CHR after 4 weeks, and a complete cytogen-
etic response (CCyR) at 3 months. Major molecular re-
sponse (MMR) was also achieved and in the subsequent
specimens taken at 10, 12 and 18 months, ETV6-ABL1
mRNA was no longer detectable with nested RT-PCR.
Both CCyR and MMR are sustained to date 22 months
from diagnosis.
Methods
(i) Cell Culture and chromosome studies
Bone marrow (BM) and peripheral blood (PB) cell sam-
ples were cultured in RPMI medium following routine
protocols as previously described [11]. High-resolution
chromosome banding analysis was carried out and ISCN
2013 nomenclature was used to describe chromosome
abnormalities [18].
(ii) FISH and molecular cytogenetic analysis
Fluorescence in situ hybridization (FISH) investigations
were performed using commercially available BCR-ABL1
probes (dual fusion probe,Vysis, USA) and ETV6 (break-
apart probe Vysis, USA). Chromosome mapping of the
9q34 regions was carried out with a range of BAC clones
(BACPAC Resources, USA). For disease monitoring a
double fusion dual colour FISH probe was made with
BAC clones covering the regions of ABL1 (RP11-57C19
and RP11-83 J21), ETV6 (RP11-356 K6, RP11-418C2
and RP11-639O1) and NOTCH1 (RP11-707O3 and
RP11-678D10) genes.
(iii) RT-PCR
Total RNA was extracted from the cell culture using
Trizol reagent (Life Technologies, USA). Purified RNA was
reverse transcribed, quality controlled and tested for BCR-
ABL1 as described previously [27] ETV6-ABL1 was ampli-
fied in pretreatment samples by single step PCR using
primers Tel3F2 (5’-CGCTATCGATCTCCTCATTCA-3’)
and CA3-b: (5’-ACACCATTCCCCATTGTGAT-3’). Two
products were amplified, corresponding to a fusion ETV6
exon 4 to ABL1 exon 2 and ETV6 exon 5 to ABL1 exon 2.
Remission samples were tested by nested PCR using
primers TEL3F: (5’-CTGCTGACCAAAGAGGACTT-3’)
and CA3-: (5’-TGTTGACTGGCGTGATGTAGTTGC
TTGG-3’) in the first step and Tel32F2 + CA3-b in the
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control DNA indicated a sensitivity of detection of 10-4.
(iv) Array Comparative Genomic Hybridisation (aCGH)
Array CGH analysis was performed with a high-density
customised 400 K oligonucleotide platform enriched
with probes covering the coding regions of oncogenes
(ID 027193, Agilent technologies, USA) following the
manufacturer’s protocol. In brief, 1500 ng genomic test
DNA was hybridised against a reference of a pooled
DNA samples collected from PBMC of 6 - 8 disease free
individuals (Promega, UK). We used Genomic Work-
bench v.6 (Agilent technologies, USA) for data analysis
as previously [28].
Results
(i) Philadelphia chromosome and BCR/ABL1 fusion are
absent
G banding analysis of bone marrow cultures found both
homologues of chromosome 22 intact, but identified a
translocation of the long arm of chromosome 9 due to t
(9;12)(q34;p13) (Figure 1a). FISH analysis using a dual
fusion, dual colour BCR-ABL1 probe (Vysis) confirmed
the absence of a fusion gene and hence the Philadelphia
chromosome. However, some 21% of the interphase BMFigure 1 Representative Philadelphia negative metaphase bone marr
karyotype; (b) FISH analysis demonstrates lack of BCR-ABL1 fusion but revea
split signal (arrowed in red) on der(9)t(9;12) from the break-apart FISH prob
red/green fusion signal marks the normal gene.cells were found to harbour a third, albeit significantly
smaller, ABL1 signal found to be absent from the meta-
phases. The ABL1 part of the D-FISH probe is 650 Kb
long and any break upstream of exon 2 would result in
two different in size segments. The proximal fragment
covering the ASS – ABL1 exon 2 region is larger (~500
Kb) and will remain on der(9)t(9;12). However, the FISH
signal from the smaller distal segment (~150 Kb)
encompassing ABL1 exon 2 to 11 was not found on the
der(12)t(9;12) chromosome as expected, although
detected in some of the interphase cells (Figure 1b).
(ii) Formation of the ETV6-ABL fusion at der (9)t(9;12)
(q34;p13)
A commercial ETV6 break-apart probe (Vysis) yielded a
split signal located on der(9)t(9;12) in all dividing and
92% of the interphase BM cells demonstrating the re-
arrangement (Figure 1c). RT-PCR using published
primers identified both type A and B transcripts of the
ETV6-ABL1 fusion thus confirming ABL1 involvement
[10]. However, such transcripts are unlikely to be a dir-
ect result of the t(9;12)(q34;p13) because of the different
orientation of the ETV6 and ABL1 genes. Furthermore,
extensive research has already shown [4,10] that the for-
mation of a functional ETV6-ABL1 fusion gene requiresow cell with a t(9;12)(q34;p13) translocation. (a) G-banded
ls a small third signal from the ABL1 probe (arrow) and; (c) The ETV6
e shows the gene rearrangement and confirms G banding results. The
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ABL1 signals on the der(12)t(9;12) in metaphase cells
prompted us to search the 9q34 region by FISH ‘walking’
for multiple events that could facilitate the formation of
the ETV6-ABL1 fusion (Figure 2). We detected a single
break within 12p13 region and translocation of the 5’
part of the ETV6 gene (exon 1-5) some 40 Kb distal of
the NOTCH1 gene (Figure 1c). This was shown by the
presence of the BAC RP11-707O3 on der(9)t(9;12), while
the distally located RP11-678D10 is moved to der(12)t
(9;12). This FISH signal pattern suggests that ETV6
exons 1 - 5 sequences are located distally to ABL1 (Figure 2,
Additional files 1 & 2). Indeed the ABL1 gene appears un-
affected since FISH analysis of dividing cells shows both
BAC clones that encompass the entire gene (i.e. RP11-
57C19 and RP11-83 J21) within the 9q34 region of der
(9)t(9;12). In contrast, FISH using either custom 9q34
BAC clones or commercial BCR-ABL1 probes on inter-
phase cells where the chromatin is less condensed
allowing the discrimination of closely spaced DNA
probes, revealed a third ABL1 signal indicatingFigure 2 FISH mapping of 9q34 and 12p13 regions in t (9;12)(q34;p13
map of the BAC clones used for FISH analysis. Red arrows indicate breakpo
ABL1 (RP11-83 J21 in red) on der(9)t(9;12) co-localizing with the 5’ part of t
5.63 Mb distal to ABL1, is flanked proximally by RP11-707O3 (green) which
RP11-678D10 (red) which has moved to der(12)t(9;12) (arrowed).breakage. The application of a cocktail of BAC clones in
a three colour FISH experiment covering all relevant
breakpoints in 12p13, 9q34.12 and 9q34.3, showed that
in interphase cells the ETV6-ABL1 fusion is a consider-
able distance away from the proximal part of ABL1
(exon 1b-2) and the neighbouring NOTCH1 gene
(Figure 3, arrows), while in metaphase cells their dis-
crimination is impossible. The ETV6-ABL1 fusion (both
type A and type B transcripts) was confirmed by the
RT-PCR and shown to occur after the break in the exon
1a-2 region of ABL1 and exon 5 of ETV6 as expected.
Whole genome scanning using oligonucleotide arrays
revealed a total of 37 cryptic copy number aberrations
(CNAs), mostly (24/37) gains (Additional file 3). A clus-
ter of CNAs was found within 9q33-qter including extra
copy of the DAB2IP (a tumour suppressor gene with a
recognised role in breast and prostate cancer) and
within the regions flanking NOTCH1. A cryptic 140 bp
loss at chr12: 12,045,340 – 12,045,484 was found at the
breakpoint in the ETV6 gene (arrowed in Additional file 3).
Other affected genome sites include the TNK2 gene at). (a) Diagram of 9q34 (top) and 12p13 chromosome regions with a
int positions in 9q34.12, 9q34.3 and 12p13.2; (b) Exons 2-11 of the
he ETV6 gene (RP11-418C2 in green) and (c) The break at 9q34.3,
houses the NOTCH1 gene and remains in der(9)t(9;12) and distally by
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MAPK15 genes among others and extra copies of the
MLL gene at 11q23 as well as MLLT1 at 19p13. Among
the loci found deleted are transcription co-activator gene
CREBBP at 16p13.3 and CBFb at 16q22 (Additional
file 3). It is noteworthy that only 2 of the 37 CNAs in this
molecular karyotype are reported polymorphic imbal-
ances, the rest represent cryptic secondary changes indica-
tive of genome instability.
Discussion
ETV6 is one of the six genes known to form fusion
chimeric transcripts with ABL1. As a rule, the fusion
gene results from joining the 3’sequences of ABL1 with
the 5’ end of the partner genes. While most of these fu-
sion genes are associated with a specific type of leukae-
mia, BCR-ABL1 and ETV6-ABL1 are found in a wide
spectrum of clinically and morphologically different ma-
lignant blood conditions [2]. In spite of their heterogen-
eity these conditions are likely to share a common
progenitor cell, the pluripotent stem cell, since both
chimeric genes activate similar transduction pathways
with similar transforming activity [29].
The ETV6-ABL1 fusion gene is a truly rare event. So
far there are 29 cases including the present study pub-
lished after the first report in 1995 by Papadopoulos
et al. (summarised in Table 1). The rarity of this fusion
is due to the opposite transcriptional orientation of the
two genes relative to the centromeres, which would re-
quire at least two events to form an in-frame fusion
transcript. It is therefore not a surprise that theFigure 3 Representative cells with FISH signals showing the cryptic th
with t(9;12)(q34;p13). BAC clones covering the regions of interest are as f
707O3&RP11-678D10, in blue) and ETV6 (RP11-418C2 & RP11-36 K5, in gree
cluster at der(9)t(9;12) in a metaphase cell (arrows) (b) in a non-dividing ce
separated from the co-localized ABL1 (exons 1b-2) and NOTCH1 signals (red
the normal 9 homologue and signals from ETV6 (green) and RP11-678D10chromosome rearrangement producing the fusion gene
often remains hidden. Perhaps the ETV6-ABL1 fusion is
not as rare as the literature suggests since there are no
satisfactory commercial FISH probes available for the
detection of the ETV6-ABL1 fusion. In dividing cells
with t(9;12)(q34;p13), the dual colour/dual probe BCR/
ABL1 set (D-FISH) should indicate an ABL1 rearrange-
ment by producing a third ABL signal on der(12) while
BCR remains intact (Figure 1b). Unfortunately this ab-
normal signal pattern was not seen in metaphase cells in
nearly a third of cases (27%) where both parts of the
rearranged ABL1 remain within the 9q34/qter (Table 1).
The situation is worse in interphase cells where the third
signal may remain unaccounted for due to its small size
as illustrated in our case and seen in a further 6 reports
with ETV6-ABL1 fusion (Table 1). Analysts using widely
available BCR-ABL1 commercial assays on interphase
cells may regard the disproportionately small third signal
from the ABL1 probe as ‘noise’. In contrast, FISH with
the ETV6 break-apart (BA) probe will produce a split
(third) signal at the der(9) chromosome that is easy
to detect in interphase cells of fusion carriers (see
Figure 2c). Therefore FISH screening with ETV6 (BA)
probe of samples suspected for CML but negative for
BCR-ABL1 rearrangement by FISH, provides a reliable
way to reassess the ‘rarity’ of this fusion gene. Indeed
two recent studies [4,5] have indicated that the inci-
dence of ETV6-ABL1 fusion transcript may well be
around 1%, thus confirming our concerns that the oc-
currence of this translocation in haematological diseases
is underestimated.ree way rearrangement of ABL1, NOTCH1 and ETV6 associated
ollows: ABL1 (RP11-83 J21 & RP11-57C19, in red), NOTCH1 (RP11-
n) (a) FISH signals from all three genes - ETV6, ABL1 and NOTCH1 -
ll the ETV6 (exons 1-5)/ABL1 (exons 2-11) fusion(green/red arrow) is
/blue arrows); while ABL1 and NOTCH1 signals (~5.6 Mb apart) mark
(downstream of NOTCH1, blue) co-hybridize at der(12)t(9;12).
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fusion products involving genes with different orienta-
tions. As a rule, formation of these fusion genes is asso-
ciated with more than one event and more than the two
breaks that are necessary for a classical reciprocal trans-
location. For example, Van Limbergen and colleagues
[10] suggested two alternative mechanism. Our findings
support a complex model (see Figure 4) that incorpo-
rates some of the suggested changes and highlight the
fact that the ETV6-ABL1 fusion resides on der(9)t(9;12)
in nearly a third of the cases thus rendering FISH with
ABL1 probes unfit for purpose.
Million et al. [30] demonstrated a striking similarity be-
tween the ETV6-ABL1 and BCR-ABL1 induced leukaemia
in mouse models, the only difference being the latency
period. They found that the ETV6-ABL1 fusion protein is
significantly more active compared to the p210 BCR-
ABL1. Importantly, both fusion proteins were shown to
have similar helix-loop-helix domains, which is fused to
the kinase domain of ABL1 and implicated in protein
oligomerisation process [31]. Indeed ETV6-ABL1 positive
patients respond to treatment with tyrosine kinase inhibi-
tors (TKI) as expected. Kawamata et al., reported a
favourable response to imatinib in chronic phase CML
with normal karyotype and ETV6-ABL1 [20]. However,Figure 4 Formation of a fusion between the ABL1 and ETV6 genes wi
balanced t(9;12)(q34;p13) results in the juxtaposition of part of the ET
(9)t(9;12) while ABL1 remains intact followed by (ii) an inversion with
(within ABL1, upstream of exon 2) and 9q34.3. This leads to formationthe inhibitory effect of imatinib was short lived and unable
to induce a complete remission in two further CML cases
[13,15]. Similarly, Nand et al., [21] reported an ETV6-
ABL1 fusion positive patient with a myeloproliferative dis-
order who developed morphologic and cytogenetic relapse
after 17 months on imatinib but achieved complete remis-
sion on a second second-generation TKI (nilotinib). After
an initial haematological response to imatinib 400 mg
daily our patient, who presented with typical chronic
phase CML and t(9;12)(q34;p13) as sole karyotype abnor-
mality, progressed at 3 months; whereas nilotinib achieved
a prompt CCyR, followed by an MMR 16 months after
diagnosis, which is sustained to date. The mechanism of
the imatinib resistance reported here and by others is still
unexplained. Although the long-term response to second
generation TKIs remains to be determined, their imple-
mentation as first line therapy in ETV6-ABL1 (+) disor-
ders is well supported.Conclusion
In summary, we highlight two main features of ETV6-
ABL1 positive disorders: firstly, the diagnostic value of
FISH with the ETV6 (BA) probe and secondly, while this
chimeric oncogene is associated with poor long termth opposite chromosomal orientation via two events: (i) firstly, a
V6 gene (exons 1-5) in the vicinity of NOTCH1 at 9q34.3 on der
in the 9q34 segment of der(9)t(9;12) after breaks at 9q34.12
of an ETV6-ABL1 fusion gene but leaves the NOTCH1 gene intact.
Gancheva et al. Molecular Cytogenetics 2013, 6:39 Page 9 of 10
http://www.molecularcytogenetics.org/content/6/1/39response to imatinib, our patient achieved a sustained
response to nilotinib.
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